Recruiting studies: Sickle B Thalassemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966 FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169 RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06213402 Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Phase 2 · 4 location(s) · New York Medical College · NCT02675959 Study of the Role of Genetic Modifiers in Hemoglobinopathies
Phase N/A · 26 location(s) · Cyprus Institute of Neurology and Genetics · NCT05799118 Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT03937817 Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimer
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT04008368 A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an
Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT05736419 Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Phase N/A · 1 location(s) · Paul Szabolcs · NCT04528355 Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Di
Phase 1 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT05904093 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338 An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
NA · 1 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT04688411 ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Phase N/A · 71 location(s) · American Thrombosis and Hemostasis Network · NCT04398628 Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Phase 1/Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT07599176 Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia an
Phase 3 · 6 location(s) · Vertex Pharmaceuticals Incorporated · NCT05477563 Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Phase 1 · 1 location(s) · Abdullah Kutlar · NCT01245179 Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Phase 2 · 1 location(s) · Paul Szabolcs · NCT01962415 Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Phase 1 · 1 location(s) · Daniel Bauer · NCT06647979

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.